It is demonstrated that aberrant Sonic Hedgehog (SHH) signaling during embryonic Choroid Plexus (CP) development triggers a dedifferentiation cascade that reverts mature epithelium to a progenitor-like state and identifies that these tumor cells cultivated in vitro are vulnerable to ATR and CDK inhibition.
Abstract
Choroid Plexus tumors constitute 10–20% of brain tumors in infancy. Among these, Choroid Plexus Carcinomas (CPC) are highly aggressive and result in poor survival. Details on tumor initiation and oncogenic events remain largely unknown, aside from a high prevalence of TP53 mutations and marked chromosomal instability. We generated hGFAP-cre::lsl-MYCN::lsl-Gli2(N)::Tp53fl/fl mice with recombination activity from embryonic day 13.5 onwards in CNS cells, leading to MYCN and Gli2 activation as well as TP53 inactivation. 84% of the mice developed ventricular tumors within 18 days of life, resembling human CPCs in histology and marker expression. We performed histological and molecular characterization of the resulting tumors and treated tumor cells in vitro. We demonstrate that aberrant Sonic Hedgehog (SHH) signaling during embryonic Choroid Plexus (CP) development triggers a dedifferentiation cascade that reverts mature epithelium to a progenitor-like state. Spatial transcriptomic analysis identifies a distinct cellular hierarchy, where differentiated plexus cells shed their secretory identity to adopt malignant progenitor states. This transformation is accompanied by a transition from multiciliated epithelial cells expressing mature, secretory CP markers to highly proliferative, monociliated progenitors expressing SOX2. This malignant reprogramming activates embryonic developmental programs and induces a critical dependency on cell cycle and DNA repair pathways. Consequently, we identify that these tumor cells cultivated in vitro are vulnerable to ATR and CDK inhibition.
It is found that PAX5, a neural/lymphatic transcription factor, contributed to neuroendocrine (NE) lineage transition, and targeting PAX5 and its downstream signaling may modulate lineage transitions responsible for treatment failure in both SCNCs and adenocarcinomas.
Ailing Wu, Yujie Hao, Xuemiao Yan et al.· Journal of Clinical Investig...· 0 citations
SUMMARY Glioma stem-like cells (GSCs) exploit developmental signaling programs that contribute to glioblastoma heterogeneity and therapy resistance. Here, we define a role for the arginine methyltransferase coactivator-associated arginine methyltransferase 1 (CARM1) in regulating GSC lineage state and survival signalin...
Dejauwne L Young, Stephanie Stransky, Maria G Molero et al.· Cell Reports· 0 citations
Amplification and high expression of MYCN and MYC are recurrent features of medulloblastoma and other pediatric cancers, yet how these proto-oncogenes interact with developmental programs to initiate tumorigenesis remains unclear. Here, we combine the experimental accessibility of the avian embryo with single-cell tran...
Lauranne Bouteille, William Fargues, Paul de Boissier et al.· bioRxiv· 0 citations
Human LUAD analyses support these progenitor programs as clinically relevant features of PRKCI-ECT2 gain and show that elevated PKCι-ECT2 signaling rewires tumor trajectory in a cell-of-origin-dependent manner.
Duy T Nguyen, Kayleah M Meneses, Cheng Zhang et al.· Cell Reports· 0 citations
It is demonstrated that TUG1, which is highly expressed in tumors, regulates early embryonic development in mice and is transformed from a cancer-specific effector to a critical regulator of the ZGA, raising the possibility that related regulatory principles may operate in other biological contexts.
Jian-Wu Wang, Guang Yang, Qingbo Yang et al.· Cellular and Molecular Life...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.